Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million on August 18, 2023. In similar transaction Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY90 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.26 CNY | -1.20% | -2.94% | -29.16% |
1st Jan change | Capi. | |
---|---|---|
-29.16% | 141M | |
+29.82% | 682B | |
+30.35% | 586B | |
-3.75% | 364B | |
+17.73% | 327B | |
+3.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.37% | 165B |
- Stock Market
- Equities
- 600671 Stock
- News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
- Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million.